Loading...
Prior phase 3 trials established autologous stem cell transplant (ASCT) consolidation and maintenance rituximab as standards of care in younger, transplant-eligible patients with previously untreated mantle cell lymphoma (MCL). Now, investigators report a multinational, industry-sponsored, phase 3 trial testing incorporation of the Bruton tyrosine kinase inhibitor (BTKi) ibrutinib into induction and maintenance therapy.
A total of 870 patients (median age, 57 years; 76% male; 98% white) were randomized to one of three regimens:
Six alternating cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and rituximab, dexamethasone, cytarabine, and cisplatin (R-DHAP), followed by ASCT consolidation in responding pa…